Roche is making a $550 million investment to expand its Diagnostics site in Indianapolis, with plans to establish the location as a major manufacturing hub for continuous glucose monitoring (CGM) systems. The investment is part of Roche’s broader strategy to strengthen its North American manufacturing capabilities and reduce its reliance on imports, particularly amid ongoing trade disruptions and tariff challenges.
The expansion is expected to create hundreds of high-skill manufacturing jobs and thousands of construction jobs, contributing significantly to the local economy. This move aligns with Roche’s effort to bolster its domestic production and mitigate the effects of tariffs imposed during the Trump Administration.
Roche’s Accu-Chek SmartGuide CGM system is at the heart of the expansion. The system, which received a CE mark in July 2024, aims to advance the company’s CGM technology pipeline. However, it is still awaiting FDA approval.
This investment highlights Roche’s commitment to expanding its CGM capabilities and ensuring a strong manufacturing presence in the U.S., potentially positioning it as a leader in the market for diabetes management systems in the coming years.
Follow MEDWIRE.AI for the latest updates on global investments in medical technology.
